Aberrant glycosylation is a hallmark of cancer that contributes to the disease’s ability to evade the immune system. As the MHC processing pathways communicate cellular health to circulating CD8+ and CD4+ T-cells, MHC-associated glycopeptides are likely a source of neoantigens in cancer. In fact, recent advances in mass spectrometry have allowed for the detection and sequencing of tumor-specific glycopeptides from the MHC class I and class II processing pathways. Here, we describe methods for detecting, sequencing, and modeling these MHC-associated glycopeptides.
CITATION STYLE
Malaker, S. A., & Ferracane, M. J. (2019). Mass Spectrometric Identification and Molecular Modeling of Glycopeptides Presented by MHC Class I and II Processing Pathways. In Methods in Molecular Biology (Vol. 2024, pp. 269–285). Humana Press Inc. https://doi.org/10.1007/978-1-4939-9597-4_17
Mendeley helps you to discover research relevant for your work.